Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.35 |
| ▸ | FNTB | P49356 | 5/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25781207 | 0.90 | CYP4F2 (0.37) | FNTAFNTBPGGT1BKCNH2GRM5 | |
| SCHEMBL25772189 | 0.88 | CYP4F2 (0.38) | HRH3 | |
| SCHEMBL25772697 | 0.86 | KMT2A (0.34) | FNTAFNTBPGGT1BKCNH2GRM5 | |
| SCHEMBL25772135 | 0.83 | CYP4F2 (0.37) | GRM5 | |
| SCHEMBL25773868 | 0.82 | CCR5 (0.35) | FNTAFNTBPGGT1BKCNH2CCR5 | |
| SCHEMBL25781205 | 0.80 | CYP4F2 (0.39) | KCNH2 | |
| SCHEMBL25781417 | 0.79 | OXER1 (0.43) | GRM5 | |
| SCHEMBL25772194 | 0.78 | RORC (0.38) | — | |
| SCHEMBL25781504 | 0.78 | EGLN2 (0.35) | GRM5HPGD | |
| SCHEMBL25772874 | 0.77 | MAOB (0.38) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023115203-A1 | OXER1 ANTAGONISTS AND USES THEREOF | FAIRHAVEN PHARMACEUTICALS INC. (CA) | 2023-06-29 | — | — | WO | disclosed |